Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

21 October 2002

Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer.

Pratik Kumar, Madan Mohan Rehani, Lalit Kumar, Raju Sharma, Neerja Bhatla, Rajvir Singh, K. Ramaiyer Sundaram

Med Sci Monit 2002; 8(10): CR667-674 :: ID: 4872

Abstract

BACKGROUND: Response prediction in patients undergoing chemotherapy for ovarian cancer is an important issue, since the cure rate is only about 15-20%. We attempted to develop a semi-empirical model to predict response in individual cases after the first cycle of chemotherapy. MATERIAL/METHODS: This prospective study included 51 cases of advanced ovarian cancer. A method was standardized to estimate ovarian tumor volume accurately from CT scan films. This permits the inclusion of patients who have undergone CT scan elsewhere. Patients underwent 4-6 cycles of chemotherapy and tumor volume was estimated after each cycle. This yielded a tumor regression curve for each patient. RESULTS: Percent reduction in tumor volume after the first chemo-cycle was a significant prognostic factor in multivariate analysis. Depending upon the rate of regression patients could be classified into Fast Regressing FR (n=29) and Moderately Regressing MR (n=16), whereas 6 patients showed Progressive Disease (PD) despite ongoing chemotherapy. The median survivals for the FR, MR and PD groups were 29.3, 18.9 and 8.5 months respectively. We found that 'percent reduction in volume after first chemo-cycle' could categorize a patient as FR/MR/PD correctly in 94.1% of cases. This parameter could also detect 5 out of 6 inherently resistant PD cases, who would otherwise undergo further chemotherapy, since early detection of resistance by clinical monitoring is quite difficult. CONCLUSIONS: An individual patient at risk for shorter survival and with inherent drug resistance can be identified after the first cycle of chemotherapy.

Keywords: Ovarian Neoplasms - drug therapy

Add Comment 0 Comments

Editorial

01 February 2025 : Editorial  

Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers

Dinah V. Parums

DOI: 10.12659/MSM.948255

Med Sci Monit 2025; 31:e948255

0:00

In Press

Clinical Research  

Immune Dysregulation in Acute Herpes Zoster: Predictive Factors for Postherpetic Neuralgia

Med Sci Monit In Press; DOI: 10.12659/MSM.944688  

0:00

Clinical Research  

Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.947202  

Laboratory Research  

Comparison of Color Stability Between Single-Shade and Conventional Composite Resins Following Immersion in...

Med Sci Monit In Press; DOI: 10.12659/MSM.946784  

Clinical Research  

Evaluation of Knowledge, Attitudes, and Practices Toward Thyroid Nodules in 456 Patients with Thyroid Nodules

Med Sci Monit In Press; DOI: 10.12659/MSM.945732  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,966,841

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   701,694

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   25,087

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   19,746

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750